Heart Failure Management: SGLT2i and GLP-1 RA Mechanism of Action

[CE contact hours--see below.] Often prescribed for obesity, SGLT2is and GLP-1 RAs have a role in heart failure management. Learn about their mechanisms of action, and how their use extends beyond weight loss to cardioprotective and renalprotective properties. Guests: Kim Newlin, MSN, ANP, FPCNA, of Sutter Roseville Medical Center in Northern California, and Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA, from the University of Colorado in Denver.  

CE Link: https://pcna.net/?p=10718&post_type=o...



2022 AHA/ACC/HFSA 2022 Guideline for the Managment of HF: https://www.ahajournals.org/doi/10.11...



Pocket Guide: Guidelines for Managing CVD Risk in Patients with Diabetes: https://pcna.net/clinical-resources/p...



HF Pocket Guide: A Guide to Prevention and Management: https://pcna.net/clinical-resources/p...



New and Emerging Treatments for Heart Failure: HFrEF and HFpEF (CE course): https://pcna.net/online-course/new-an...



SGLT2is in Heart Failure: ncbi.nlm.nih.gov/pmc/articles/PMC8654149/



SGLT2i in HFpEF: multicenter randomized trial: nature.com/articles/s41591-021-01536-x



Empagliflozin in HFpEF: https://www.nejm.org/doi/10.1056/NEJM....